Compare AngloGold Ashanti Limited (AU) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Sana Biotechnology Inc — how do they compare? AngloGold Ashanti Limited trades at $98 (market cap $49.28B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: AngloGold Ashanti Limited is far larger — about 43.6× Sana Biotechnology Inc's market cap, and AngloGold Ashanti Limited pays a 4.64% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| AU | SANA | |
|---|---|---|
Market Cap | $49.28B | $1.13B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $5.92 |
52-Week Low | $52.15 | $2.68 |
Enterprise Value | $48.29B | $1.05B |
Dividend Yield | 4.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $98.20, up 0.98% today, near its 52-week high. The stock shows strong fundamental momentum with revenue surging to $9.89B in 2025 and net income reaching $2.64B. Analysts maintain a bullish consensus with a $120.33 price target, supported by robust cash flow and a $2B buyback program. Technical indicators are mixed, with moving averages bullish but RSI levels suggesting overbought conditions. Recent news highlights operational strength and institutional accumulation.
Outlook remains positive driven by gold price strength and production growth, but risks include commodity volatility and operational execution. The stock offers value with a P/E of 13.06 and high profitability margins, though overbought technicals may prompt near-term consolidation. Investor sentiment is favorable, but macroeconomic factors could impact performance.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
